Menopausal Hot Flashes Market Report 2026

The menopausal hot flashes market size has grown strongly in recent years. It will grow from $15.92 billion in 2025 to $16.88 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to aging female population, increased life expectancy among women, widespread use of hormone replacement therapy, growing awareness of menopausal health, expansion of gynecological healthcare services.

The menopausal hot flashes market size is expected to see strong growth in the next few years. It will grow to $21.68 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rising demand for safer non-hormonal therapies, growth in menopause-focused healthcare programs, increasing focus on women’s health research, expansion of online and digital health consultations, growing acceptance of alternative treatment methods. Major trends in the forecast period include rising preference for non-hormonal treatment options, growing awareness and diagnosis of menopausal symptoms, increasing adoption of alternative and lifestyle-based therapies, expansion of personalized menopause management approaches, higher demand for long-term symptom management solutions.

Government-led initiatives focused on women’s health during menopause are anticipated to drive the growth of the menopausal hot flashes market in the coming years. Government initiatives for menopausal health include targeted programs, funding allocations, and policy measures designed to improve healthcare delivery, promote research, and expand access to services for women experiencing menopause-related symptoms. Such initiatives are becoming more prevalent as governments increasingly acknowledge the importance of improved awareness, timely diagnosis, and effective treatment options to support women during the menopausal transition. The menopausal hot flashes market gains from these efforts through enhanced research support, faster innovation, and broader availability of evidence-based therapies for symptom management. For example, in January 2023, according to the Government of New South Wales, an Australia-based government authority, funding of $0.0403 billion was allocated over four years (2022-2023 to 2025-2026) to establish up to 16 new programs aimed at supporting women with severe menopausal symptoms. As a result, government initiatives for women’s health in menopause are contributing significantly to the expansion of the menopausal hot flashes market.

Leading companies in the global menopausal hot flashes market are prioritizing the development of innovative treatment approaches, including non-hormonal neurokinin-3 (NK3) receptor antagonists, to offer safer and more effective options for women who are unable or unwilling to use hormone therapy. Non-hormonal NK3 receptor antagonists are targeted therapies that act by inhibiting neurokinin-3 receptors in the brain’s thermoregulatory center, thereby lowering the frequency and severity of vasomotor symptoms such as moderate to severe hot flashes. For example, in May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval from the Food and Drug Administration (FDA) for Veozah (fezolinetant), an oral treatment indicated for moderate to severe vasomotor symptoms associated with menopause. Veozah is the world’s first non-hormonal NK3 receptor antagonist specifically developed for menopausal hot flashes. It provides a novel non-hormonal mechanism of action, convenient once-daily oral administration, and clinically proven reductions in both the frequency and intensity of vasomotor symptoms, marking a significant advancement for women seeking non-hormonal relief from menopause-related symptoms.

In November 2023, Pharmavite LLC, a US-based nutrition-powered wellness company, acquired Bonafide Health for $42 million. Through this acquisition, Pharmavite seeks to reinforce and expand its women’s health portfolio by incorporating Bonafide Health’s clinically validated menopause and midlife wellness solutions into its existing offerings. Bonafide Health LLC is a US-based women’s health company focused on developing and delivering non-hormonal, plant-based supplements specifically formulated to help alleviate menopausal hot flashes.

Major companies operating in the menopausal hot flashes market are Pfizer Inc., Johnson & Johnson, The Procter & Gamble Company, Merck & Co. Inc., Bayer AG, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Gedeon Richter Plc, Lupin Limited, Hisamitsu Pharmaceutical Co. Inc., Noven Pharmaceuticals Inc., Ligand Pharmaceuticals Inc., Mithra Pharmaceuticals SA, TherapeuticsMD Inc., Theramex Ltd., Ascend Therapeutics Inc., EndoCeutics Inc., Sermonix Pharmaceuticals LLC, Ralington pharma LLP.

North America was the largest region in the Menopausal Hot Flashes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menopausal hot flashes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the menopausal hot flashes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the menopausal hot flashes market by increasing costs related to imported pharmaceutical ingredients, supplements, and formulation components used in hormonal and non-hormonal therapies. The impact is most evident in branded medications and herbal supplements, particularly in regions dependent on imported drugs such as Asia-Pacific and Latin America. Higher costs have affected pricing across retail and hospital pharmacies. However, tariffs have also encouraged local drug manufacturing, generic formulation development, and supply chain diversification, supporting long-term market accessibility.

The menopausal hot flashes market research report is one of a series of new reports that provides menopausal hot flashes market statistics, including menopausal hot flashes industry global market size, regional shares, competitors with a menopausal hot flashes market share, detailed menopausal hot flashes market segments, market trends and opportunities, and any further data you may need to thrive in the menopausal hot flashes industry. This menopausal hot flashes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Menopausal hot flashes, also referred to as vasomotor symptoms, are common experiences during menopause and perimenopause and often present as sudden waves of intense heat accompanied by sweating and flushed skin in women. These episodes can be bothersome and distressing, leading to physical discomfort, heightened anxiety, and disturbances in sleep.

The primary categories of treatment for menopausal hot flashes include hormonal therapies, non-hormonal therapies, and alternative approaches. Hormonal therapy involves treatment administered during menopause, a stage when the body reduces estrogen production, and typically includes medications containing female hormones to supplement estrogen levels. The treatment pipeline encompasses drugs in phase III as well as phase I and II stages, which are distributed through multiple channels such as retail pharmacies, online pharmacies, and hospital pharmacies. The key application groups include women aged 51-55 years, 46-50 years, and 40-45 years.

The menopausal hot flashes market consists of revenues earned by entities by providing estrogen therapy, and menopause hormone therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The menopausal hot flashes market also includes sales of venlafaxine, paroxetine, and escitalopram. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.